ArticleOrphanet journal of rare diseases2025
European experience of steroid therapy in children with developmental and epileptic encephalopathy with spike wave activation in sleep ((D)EE-SWAS).
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep: Pathophysiological insights and treatment options.Epilepsia · 2026Review
- Developmental and/or Epileptic Encephalopathy with Spike-Wave Activation in Sleep: From Thalamocortical Mechanisms to Precision Therapy.Children (Basel, Switzerland) · 2026Review
- Epilepsy grand challenge 2025.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDevelopmental and epileptic encephalopathy with spike wave activation in sleep (DEE-SWAS) and epileptic encephalopathy with spike wave activation in sleep (EE-SWAS) are rare but well-known childhood epileptic disorders. Steroids are one of the first line treatment options, but a variety of steroid regimens exists. The aim of this survey was to evaluate the practices of steroid therapy in the treatment of (D)EE-SWAS across European centers.
methodsAn online survey was conducted (via 'SurveyMonkey' Europe) among European epilepsy centers. Questions asked included: characteristics of replying center, applied definition of DEE-SWAS, existence of regional/national guidelines regarding diagnostic and therapeutic management. Particular attention was paid to the indication/contraindication of steroids and treatment regimens used.
resultsResponses were obtained from 60 centers across 18 countries. Only 15% of centers reported the availability of national guidelines for the management of (D)EE-SWAS. There were variations in definition of (D)EE-SWAS, with Spike-Wave- Index (SWI) > 85 (irrespective of cognitive status) and SWI > 50% with concurrent neurodevelopmental regression being the most prevalent, reported in 36% and 50%, respectively. Steroids and clobazam were considered the predominant treatment options, with the primary indication for steroids being neurodevelopmental arrest (52%) and failure of clobazam treatment (51%). Treatment goals of steroid treatment primarily focused on neurodevelopmental improvement (95%), and reduction of SWI (66%). Methylprednisolone and prednisone were the most frequently used steroids, although other steroid types were also reported. Pulse therapy was utilized exclusively in 47% of centers. The most commonly used steroid regimen was intravenous/oral methylprednisolone pulse therapy (20 mg/kg/day for 3 days, either monthly or weekly), although a broad variety of different regimens were reported. Criteria influencing decisions about steroid treatment were largely based on personal experience, with scientific publications playing a role in decision-making in only 14% of centers.
conclusionSteroids are part of the first line therapy of (D)EE-SWAS across Europe, but heterogeneity in formulations, dosages, and regimens persists due to limited guideline availability. The absence of comparative studies and the discordant definitions of (D)EE-SWAS further hinder comparisons of treatment efficacy. We recommend that harmonizing steroid treatment strategies is imperative for optimizing (D)EE-SWAS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.